Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer

doi:10.3748/wjg.v25.i37.5590

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 37

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9698)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series.

Item

Count

PDF

776

WORD

214

HTML

6142

Figures (1-6)

290

Sum=7422

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

842

Download

1434

Sum=2276

Oct 7, 2019 (publication date) through Aug 26, 2024

Times Cited of This Article

Times Cited (24)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Oct 7, 2019; 25(37): 5590-5603
Published online Oct 7, 2019. doi: 10.3748/wjg.v25.i37.5590

Full Size Figure Download Figure

Figure 3 Expression of ADAM28 in collected clinical pancreatic cancer tissues. A: A total of 16 pancreatic cancer tissues and the corresponding adjacent normal tissues were analyzed. ^cP < 0.001 vs normal group; B: The respective ratio between tumor and adjacent normal tissues (T/N) showed as a bubble chart. T: Tumor tissue; N: Normal tissue; PDAC: Pancreatic ductal adenocarcinoma.

Citation: Wei L, Wen JY, Chen J, Ma XK, Wu DH, Chen ZH, Huang JL. Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer. World J Gastroenterol 2019; 25(37): 5590-5603
URL: https://www.wjgnet.com/1007-9327/full/v25/i37/5590.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i37.5590